ITC Asks for Comments on Section 337 Complaint on Hemostatic Products
The International Trade Commission is asking for comments by March 17 on a complaint filed by Baxter alleging violations of Section 337 of the Tariff Act by imports of patent-infringing hemostatic products by Johnson & Johnson, Ethicon, Ferrosan, and Packaging…
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
Coordinators. Baxter makes FLOSEAL, a “hemostatic matrix” that, when applied to a wound with a syringe, forms clots to stop bleeding during surgical procedures. According to Baxter’s Feb. 28 complaint, Ferrosan makes a similar product, SURGIFLO, that infringes Baxter’s patented technologies (see 14030503). The SURGIFLO is then imported by Johnson & Johnson and Ethicon, said Baxter. Packaging Coordinators turns the SURGIFLO into ready-to-use kits for Ferrosan and Ethicon, it said. Baxter is requesting limited exclusion orders and cease and desist orders banning import and sale of infringing merchandise by Ferrosan, Johnson & Johnson, Ethicon, and Packaging Coordinators.